Last reviewed · How we verify
CHF5633
CHF5633 is a small molecule in development for the treatment of cystic fibrosis.
CHF5633 is a small molecule in development for the treatment of cystic fibrosis. Used for Treatment of cystic fibrosis.
At a glance
| Generic name | CHF5633 |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | CFTR corrector |
| Target | CFTR |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
CHF5633 is a CFTR corrector that aims to improve the function of the cystic fibrosis transmembrane conductance regulator protein, thereby alleviating the symptoms of cystic fibrosis.
Approved indications
- Treatment of cystic fibrosis
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC) (PHASE2)
- First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF5633 CI brief — competitive landscape report
- CHF5633 updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI